+ Site Statistics
+ Search Articles
+ PDF Full Text Service
How our service works
Request PDF Full Text
+ Follow Us
Follow on Facebook
Follow on Twitter
Follow on LinkedIn
+ Subscribe to Site Feeds
Most Shared
PDF Full Text
+ Translate
+ Recently Requested

Consensus statement of professional associations on prescribing of PCSK9-inhibitors

Consensus statement of professional associations on prescribing of PCSK9-inhibitors

Vnitrni Lekarstvi 64(12): 1131-1136

A new class of drugs known as PCSK9 inhibitors (PCSK9i) provide biological treatment for hypercholesterolemia. These drugs are administered using a subcutaneous injection once in two or four weeks. PCSK9i are not a replacement of the existing hypolipidemics, they just expand the therapeutic spectrum for the critically ill and those who cannot use the standard therapy and do not reach satisfactory target values. There are essentially two indications: (1) hypercholesterolemie and mixed dyslipidemia and (2) secondary prevention of cardiovascular diseases (CVD). Statin intolerance is not the only indication for treatment. However as its presence sometimes plays an essential role as to choosing the treatment, it will be also discussed in the paragraph on reimbursement conditions. Reimbursement conditions (very simplified): the treatment will be provided at selected centres. A list of the centres is included in an annexe to this article. You will find it also on www.interna-cz.eu, on www.kardio-cz.cz and www.athero.cz. The indicative concentration of LDL-cholesterol (LDL-C) from which on PCSK9i can be prescribed as covered from the public health insurance, is the following: (1) familial hypercholesterolemia 4.0 mmol/l, (2) for secondary prevention CVD 3.0 mmol/l - Please note: the presented LDL-C level is one reached under maximum (tolerated) high intensity hypo-lipidemic therapy. High intensity hypolipidemic therapy is defined as atorvastatin 40-80 mg or rosuvastatin 20-40 mg + ezetimibe. In the case of demonstrated intolerance of both the mentioned statins the patient has to be treated with a maximum tolerated dose of statins, in combination with another hypolipidemic drug (ezetimibe). Statin intolerance is defined as intolerance of at least two successive statins, which results in their discontinuation. Statin intolerance alone is not the indication for PCSK9i treatment! The payment criteria must always be complied with. A medical officer can of course be asked to approve such treatment in exceptional cases. Key words: alirocumab - PCSK9 inhibitors centers - center therapy - evolocumab - familial hypercholesterolemia - proprotein konvertase subtilisin kexin 9 inhibitors (PCSK9i) - secondary prevention - statins intolerance.

Please choose payment method:

(PDF emailed within 1 workday: $29.90)

Accession: 066446362

Download citation: RISBibTeXText

PMID: 30704246

Related references

International consensus recommendations. Summary statement and additional suggested guidelines. European Consensus Conference, November 1991. American College of Chest Physicians consensus statement of 1995. International Consensus Statement, 1997. Medical Clinics of North America 82(3): 613-633, 1998

Severe hypercholesterolaemia--when to use the proprotein convertase subtilisin-kexin type 9 protease inhibitors (PCSK9 inhibitors)? Polish Society of Cardiology experts' group statement. Kardiologia Polska 74(4): 394-398, 2017

Consensus document of the Spanish Society of Arteriosclerosis on indications of inhibitors of PCSK9. Clinica E Investigacion en Arteriosclerosis 28(3): 164-165, 2017

PCSK9 inhibitors - new possibilities in the treatment of hypercholesterolemia: For which patients will be indicated?Czech atherosclerosis society statement. Vnitrni Lekarstvi 62(4): 329-333, 2016

U.K. consensus statement on safe clinical prescribing of bexarotene for patients with cutaneous T-cell lymphoma. British Journal of Dermatology 168(1): 192-200, 2013

Expert consensus on the rational clinical use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors. Hormones 15(1): 8, 2016

Prescribing privileges for non-physicians in the military. Accepted as a Consensus Statement by the ACNP Council, March 22, 1991. Neuropsychopharmacology 4(4): 290-291, 1991

Management of invasive well-differentiated thyroid cancer: an American Head and Neck Society consensus statement. AHNS consensus statement. Head & Neck 36(10): 1379-1390, 2015

Comprehensive management of recurrent thyroid cancer: An American Head and Neck Society consensus statement: AHNS consensus statement. Head & Neck 38(12): 1862-1869, 2016

Expert views as expressed in a lay consensus statement. Nordic Consensus Statement on investigation of allergy and other disorders of hypersensitivity. Allergy 49(8): 573-575, 1994

Expert consensus statement on the use of fractional flow reserve, intravascular ultrasound, and optical coherence tomography: a consensus statement of the Society of Cardiovascular Angiography and Interventions. Catheterization and Cardiovascular Interventions 83(4): 509-518, 2016

Evidence-guided prescribing of combined oral contraceptives: consensus statement. An International Workshop at Mottram Hall, Wilmslow, U.K., March, 1996. Contraception 54(3): 125-129, 1996

Management of perceived devastating brain injury after hospital admission: a consensus statement from stakeholder professional organizations. British Journal of Anaesthesia 120(1): 138-145, 2018

Consensus statement on the safety profile of topical calcineurin inhibitors. Dermatology 211(2): 77-78, 2005

The road to consensus: considerations for the safe use and prescribing of COX-2-specific inhibitors. Medical Journal of Australia 176(7): 332-334, 2002